Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
- Status
- RECRUITING
- Phase
- PHASE3
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE3
Safe Accelerated Venetoclax Escalation in CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
- Status
- WITHDRAWN
- Phase
- PHASE3
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- TERMINATED
- Phase
- PHASE1
Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
- Status
- RECRUITING
- Phase
- PHASE2
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy
- Status
- RECRUITING
- Phase
- PHASE2